9th International Review On

Gastrointestinal
Cancer 2026

Latest Evidence. Global Experts. Future of GI Oncology.

8 - 9 August 2026Saturday - Sunday
Taj SantacruzMumbai, India
Register Now Download Brochure
Gastrointestinal oncology medical illustration
500+Delegates
40+National Faculty
50+Scientific Sessions
2Days of Excellence

Healthcare Solutions Partner

Onconxt Health Solutions Private Limited

Onconxt Health Solutions Private Limited is an active, registered healthcare solutions company based in Chembur, Mumbai. Dedicated to advancing oncology care and facilitating academic & clinical exchange, Onconxt delivers innovative healthcare solutions, medical event management support, and patient-centric oncology initiatives across India.

Active & Registered Entity
Chembur, Mumbai
Oncology & Healthcare Solutions

Onconxt Health Solutions

Chembur, Mumbai

Empowering healthcare excellence and supporting specialized oncology reviews to bring global evidence, cutting-edge clinical research, and expert care closer to clinicians and patients.

9TH INTERNATIONAL ANNUAL REVIEW ON GASTROINTESTINAL CANCER

Dear Colleagues,

It gives us immense pleasure to welcome you to the 9th International Annual Review on Gastrointestinal Cancer Update, scheduled on 8th & 9th August 2026 in Mumbai. Since its inception in 2019, this annual academic gathering has evolved into a highly anticipated platform for clinicians, surgeons, medical oncologists, radiation oncologists, gastroenterologists, researchers, and healthcare professionals dedicated to advancing the field of gastrointestinal oncology.

The landscape of GI cancer management continues to change rapidly with the emergence of novel therapies, precision medicine, immunotherapy, and multidisciplinary treatment strategies, leading to significantly improved patient outcomes. In view of these advancements, this meeting is designed to provide a comprehensive review of the most important scientific data, landmark trials, practice-changing updates, and global conference highlights from the past year.

Conducted annually in Mumbai, the conference brings together renowned national and international experts to discuss current standards of care and future directions across various GI malignancies including esophageal, gastric, hepatobiliary, pancreatic, colorectal, and rare gastrointestinal cancers.

Through meaningful scientific exchange and collaborative discussions, this conference aims to enhance clinical practice, encourage evidence-based decision-making, and ultimately improve patient care outcomes across the region and beyond.

Organizers

Dr. Anil Heroor

Consultant Surgical Oncologist,
Anil Cancer Clinic, Thane, Mulund, Dombivali

Dr. Tejinder Singh

Consultant Medical Oncologist,
Apollo Cancer Center, Apollo Hospital, Navi Mumbai

Dr. Adwaita Gore

Consultant Medical Oncologist,
Saifee Hospital, Nanavati Max, Zen Hospital, Mumbai

Dr. Harshit Shah

Onco Surgeon,
Director – Empower Oncology, Mumbai

Taj Santacruz venue

About The Conference

Uniting Global Experts
Against GI Cancers

GI Cancer 2026 brings together leading oncologists, surgeons, researchers and healthcare professionals from around the world to discuss the latest advances, share knowledge and improve outcomes for patients with gastrointestinal cancers.

Know More

Agenda

Two Days of Knowledge & Innovation

View Detailed Program

  • Tislelizumab Plus Chemoradiotherapy Versus Chemoradiotherapy Alone in Locally Advanced ESCC: Interim Analysis of the Phase III TORCH-E Trial
  • Nivolumab Plus Neoadjuvant Chemotherapy Versus Chemotherapy Alone in Resectable ESCC: A Phase III Trial
  • Camrelizumab Plus Chemotherapy in Advanced ESCC: Phase III Results
  • Trastuzumab Deruxtecan in HER2-Low Esophageal Adenocarcinoma: Phase II Study
  • Dual Checkpoint Inhibition Versus Chemoimmunotherapy in Metastatic Esophageal Cancer: Phase II Trial
  • ICG Fluorescence-Guided vs Conventional Lymphadenectomy in Esophagectomy: Randomized Trial
  • Robotic vs Open Esophagectomy: Multicenter Outcomes Study
  • ctDNA-Guided Adjuvant Therapy in ESCC: Prospective Study
  • Dose-Escalated IMRT in ESCC: Phase II Trial
  • Immunotherapy Sequencing with Radiotherapy in ESCC: Randomized Study

  • Zolbetuximab Plus CAPOX in CLDN18.2 Gastric Cancer: Phase III OS Analysis
  • Bemarituzumab Plus Chemotherapy in FGFR2b Gastric Cancer: Phase III
  • Perioperative FLOT Plus Nivolumab vs FLOT Alone: Phase III
  • Trastuzumab Deruxtecan vs Chemo in HER2 Gastric Cancer: Phase III
  • Pembrolizumab vs Chemotherapy in MSI-H Gastric Cancer: Phase III
  • Robotic vs Laparoscopic D2 Gastrectomy: Randomized Trial
  • Function-Preserving Robotic Gastrectomy Outcomes Study
  • Single-Cell Analysis of CLDN18.2 Resistance
  • Adjuvant Chemoradiotherapy vs Chemo Post D2: Phase III
  • Sarcopenia Impact in Gastric Cancer Outcomes Study

  • Durvalumab Plus GemCis in BTC: Phase III OS Update
  • KRAS G12C Inhibitor Combo in Pancreatic Cancer: Phase II
  • Neoadjuvant mFOLFIRINOX vs Surgery in PDAC: Phase III
  • Liposomal Irinotecan Regimens in Pancreatic Cancer: Phase III
  • Triplet vs Doublet Chemotherapy in Pancreatic Cancer: Phase II
  • Robotic Whipple vs Open Surgery: Randomized Trial
  • Robotic vs Laparoscopic Liver Resection: Comparative Study
  • ctDNA MRD Detection in Pancreatic Cancer
  • SBRT in Borderline Resectable PDAC: Phase II
  • Y-90 Radioembolization + IO in HCC: Phase II

  • Nivolumab + Ipilimumab vs Nivolumab in MSI-H CRC: Phase III
  • KRAS G12C + Cetuximab vs Standard in CRC: Phase III
  • BRAF Triplet vs Doublet in CRC: Phase III
  • ctDNA-Guided Adjuvant Therapy in Colon Cancer: Phase III
  • T-DXd in HER2 CRC: Phase II
  • Robotic vs Laparoscopic TME: RCT
  • Robotic Right Hemicolectomy Outcomes Study
  • Tumor Microenvironment Predicting IO Response
  • TNT vs Standard Therapy in Rectal Cancer: Phase III
  • Watch-and-Wait Strategy Outcomes Study

  • Perioperative Immunotherapy Versus Adjuvant Immunotherapy Across Resectable GI Cancers: A Pooled Analysis of Phase III Trials
  • Conversion Therapy with Chemoimmunotherapy in Oligometastatic Gastrointestinal Cancers: Results from a Multicenter Phase II Study
  • Chemo-Free First-Line Treatment in Biomarker-Selected GI Malignancies: A Phase II Basket Trial
  • Optimal Sequencing of Immunotherapy and Targeted Therapy in Advanced GI Cancers: A Randomized Phase II Study
  • Real-World Outcomes of Immune-Related Adverse Event Management in GI Oncology: A Multicenter Registry Analysis
  • Integration of Robotic Surgery in Multidisciplinary GI Cancer Care: Impact on Surgical and Oncologic Outcomes
  • Artificial Intelligence–Assisted Surgical Planning in GI Oncology: A Prospective Multicenter Study
  • Circulating Tumor DNA–Guided Treatment Adaptation Across GI Malignancies: Results from a Prospective Translational Trial
  • Stereotactic Body Radiotherapy Combined with Systemic Therapy in Oligometastatic GI Cancers: A Phase II Trial
  • Enhanced Recovery After Surgery (ERAS) Protocols in GI Oncology: Impact on Morbidity, Length of Stay, and Survival Outcomes

  • Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Advanced Gastroesophageal Junction Cancer: Phase III Results
  • Zolbetuximab-Based Therapy in CLDN18.2-Positive Upper GI Cancers: Updated Survival Analysis from a Phase III Trial
  • Trastuzumab Deruxtecan in HER2-Low Gastroesophageal Adenocarcinoma: Phase II Study Results
  • Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in PD-L1 High Upper GI Tumors: A Randomized Phase II Study
  • Second-Line Immunotherapy Versus Targeted Therapy in Advanced Upper GI Malignancies: A Comparative Phase II Trial
  • Robotic Transhiatal Esophagectomy Versus Minimally Invasive Approach: A Prospective Comparative Study
  • Robotic Gastroesophageal Junction Resection: Impact on Margins and Lymph Node Yield
  • Molecular Profiling of Upper GI Tumors to Predict Response to Immunotherapy: A Translational Study
  • Proton Beam Therapy in Locally Advanced Upper GI Cancers: A Phase II Clinical Trial
  • Nutritional Prehabilitation in Upper GI Cancer Surgery: Impact on Postoperative Outcomes and Survival

  • Total Neoadjuvant Therapy Versus Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: Final Results of a Phase III Trial
  • Short-Course Radiotherapy Followed by Chemotherapy Versus Long-Course Chemoradiation in Rectal Cancer: A Randomized Study
  • Adjuvant Chemotherapy Guided by Circulating Tumor DNA in Stage III Colon Cancer: Phase III Results
  • First-Line Immunotherapy in MSI-High Metastatic Colorectal Cancer: Long-Term Outcomes from a Phase III Trial
  • EGFR Rechallenge Strategy in RAS Wild-Type Metastatic Colorectal Cancer: A Prospective Phase II Study
  • Robotic Versus Transanal Total Mesorectal Excision (TaTME): A Multicenter Comparative Study
  • Robotic Rectal Cancer Surgery: Impact on Circumferential Resection Margins and Functional Outcomes
  • Genomic Predictors of Response to Total Neoadjuvant Therapy in Rectal Cancer: A Translational Analysis
  • Dose Escalation in Preoperative Radiotherapy for Rectal Cancer: A Phase II Trial
  • Organ Preservation Strategies in Rectal Cancer Following Complete Clinical Response: Prospective Cohort Outcomes

  • Atezolizumab Plus Bevacizumab Versus Durvalumab-Based Regimens in Advanced Hepatocellular Carcinoma: A Phase III Comparative Study
  • Lenvatinib Plus Pembrolizumab in Unresectable Hepatocellular Carcinoma: Updated Results from a Phase III Trial
  • Durvalumab Plus Gemcitabine–Cisplatin in Advanced Biliary Tract Cancer: Long-Term Survival Analysis
  • FGFR Inhibitors Versus Chemotherapy in FGFR2-Altered Cholangiocarcinoma: A Randomized Phase III Trial
  • Second-Line Targeted Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
  • Robotic Liver Resection Versus Open Surgery in Hepatocellular Carcinoma: A Randomized Controlled Trial
  • Robotic Surgery for Perihilar Cholangiocarcinoma: Feasibility and Oncologic Outcomes
  • Circulating Tumor DNA as a Biomarker in Hepatocellular Carcinoma: A Prospective Study
  • Stereotactic Body Radiotherapy Versus Transarterial Chemoembolization in Unresectable HCC: A Phase II Trial
  • Downstaging Strategies for Liver Transplant in HCC: A Multidisciplinary Outcomes Study

  • Modified FOLFIRINOX Versus Gemcitabine-Based Therapy in Resected Pancreatic Cancer: Phase III Results
  • Neoadjuvant Chemotherapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Long-Term Outcomes of a Phase III Trial
  • KRAS G12D Targeted Therapy in Advanced Pancreatic Cancer: First-in-Human Phase I/II Study
  • mRNA Vaccine Therapy in Resected Pancreatic Cancer: Early Results from a Phase I Trial
  • Stromal Targeting Agents Combined with Chemotherapy in Pancreatic Cancer: A Phase II Study
  • Robotic Pancreaticoduodenectomy with Vascular Resection: A Multicenter Feasibility Study
  • Robotic Distal Pancreatectomy Versus Laparoscopic Approach: Comparative Outcomes Study
  • Molecular Subtyping of Pancreatic Cancer and Its Impact on Treatment Outcomes: A Translational Study
  • Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Cancer: A Phase II Trial
  • Multidisciplinary Management of Borderline Resectable Pancreatic Cancer: Real-World Outcomes Study

  • Artificial Intelligence–Driven Treatment Decision Models in GI Oncology: A Prospective Validation Study
  • Digital Pathology Integration in Gastrointestinal Cancer Diagnosis and Treatment Planning: A Multicenter Study
  • Personalized Neoantigen Vaccines in Gastrointestinal Malignancies: Early Phase Clinical Trial Results
  • CAR-T Cell Therapy in Solid Tumors: Initial Results in Advanced GI Cancers
  • Microbiome Modulation to Enhance Immunotherapy Response in GI Cancers: A Phase II Trial
  • Robotic-Assisted Image-Guided Surgery Using Augmented Reality in GI Oncology: A Feasibility Study
  • Next-Generation Sequencing–Guided Precision Oncology in GI Cancers: Outcomes from a Basket Trial
  • Liquid Biopsy for Early Cancer Detection in High-Risk GI Populations: A Prospective Study
  • FLASH Radiotherapy in Gastrointestinal Malignancies: First Clinical Experience Study
  • Wearable Technology for Monitoring Treatment Toxicity in GI Cancer Patients: A Prospective Study